Objectives: To describe trends in prevalence, susceptibility profile and risk factors for MDR Neisseria gonorrhoeae (MDR-NG) in England and Wales.
Introduction
Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae, is the second most commonly diagnosed bacterial sexually transmitted infection (STI) in England. 1 Although estimated prevalence in community settings in Britain is low (,0.1%), 2 recent years have seen worrying increases in diagnoses among MSM. 1, 3 The history of rapid development of resistance to antimicrobials used for treatment has made antimicrobial-resistant (AMR) N. gonorrhoeae a major global health concern and a priority area for Public Health England (PHE). [4] [5] [6] [7] [8] [9] Extended-spectrum cephalosporins (ESCs) are the most recent class of antimicrobial introduced to treat gonorrhoea and represent a 'last-line' treatment option, with no new antimicrobials available and few in development. 4, 5, 9, 10 Since 2011, recommended first-line treatment in the UK has been dual therapy with 500 mg of intramuscularly injectable ceftriaxone (an ESC) plus 1 g of oral azithromycin, in an attempt to prevent sustained resistance to ESCs becoming established, 10, 11 an approach which has been implemented in many other regions globally. 12 Although resistance to ceftriaxone is rare, recent increases in azithromycin resistance have been described, including high-level resistance. 13, 14 There is also evidence of N. gonorrhoeae becoming gradually less susceptible to ceftriaxone, 15 and the first reported global case of dual treatment failure was also detected in the UK. 16 Many have now highlighted that MDR N. gonorrhoeae (MDR-NG) poses a serious threat and untreatable gonorrhoea is an increasingly plausible prospect. 5, 7, 9, 10 It is critical to understand the epidemiology of AMR N. gonorrhoeae to inform treatment guidelines and prevention and control measures, in addition to wider gonorrhoea prevention efforts. 4, 7, 17 The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) was established in 2000 to monitor trends and provide information on determinants of AMR N. gonorrhoeae in England and Wales 18 and combines susceptibility data with demographic, behavioural and clinical information from those diagnosed with gonorrhoea at selected specialist sexual health services. GRASP has provided detailed insight into patterns of antimicrobial resistance in N. gonorrhoeae and informed changes to treatment guidelines. 10, 19 To date, GRASP data on trends and risk factors for individual antimicrobials have been reported, 13, 15, 20, 21 but detailed analyses of MDR-NG have not. This project seeks to fill this knowledge gap by investigating the prevalence, resistance profile and risk factors for MDR-NG in England and Wales in order to understand implications for the future treatment of gonorrhoea and contribute to the scant epidemiological literature on MDR-NG.
7,22-27

Methods
Ethics and governance
PHE has permission to handle data obtained by GRASP under section 251 of the UK National Health Service Act of 2006, which was renewed annually by the Ethics and Confidentiality Committee of the National Information Governance Board until 2013. Since then, the power of approval of public health surveillance activity has been granted directly to PHE.
Data sources
Detailed descriptions of GRASP methodology have been published previously. 13 Briefly, isolates from individuals with gonorrhoea attending 27 specialist sexual health clinics in England and Wales during a threemonth period each summer between 2004 and 2015 were cultured and submitted to PHE for susceptibility testing. An agar dilution method was used to determine MICs of ceftriaxone, cefixime, spectinomycin, azithromycin, penicillin and ciprofloxacin. Susceptibility data were matched to demographic, clinical and behavioural data submitted by the clinics. All patients diagnosed with gonorrhoea during this period were eligible for inclusion; however, approximately half of episodes did not have susceptibility data due to culture not being attempted or culture not being successful. 28 
Azithromycin MIC data
The diagnostic susceptibility test (DST) medium used for susceptibility testing for GRASP isolates was changed in 2015, whereupon MICs of azithromycin, and subsequently the proportion of resistant isolates, increased. 13 A validation study compared the MICs determined by the new and old DST agars and found MICs of azithromycin were higher by approximately one dilution using the new DST medium. The new DST medium provided better pH and physiological conditions for growth of fastidious strains of N. gonorrhoeae which subsequently resulted in more reliable azithromycin MIC determination; this was also confirmed by local quality assurance data. 13 Azithromycin MIC data for 2013 and 2014 (the years in which the problems with growth on the old DST medium were seen) were therefore adjusted upwards by a factor of one dilution to enable more accurate description of trends over time.
Definition of MDR-NG
Defining MDR-NG is challenging due to differences in first-line treatments over time and internationally. We therefore present analyses of: (i) patterns of AMR N. gonorrhoeae over time, including resistance or decreased susceptibility to multiple classes of antimicrobials, to facilitate international and longer-term comparisons; and (ii) MDR-NG defined as relevant to current clinical practice in the UK. For the latter, we adapted the working definition proposed by Tapsall et al. 7 (2009): resistance or decreased susceptibility to one or more antimicrobial in widespread use to treat gonorrhoea (category 1) and resistance to two or more antimicrobials in less frequent use/little use but proposed for more frequent use (category 2). The original Tapsall et al. 7 definition included spectinomycin in category 1 and azithromycin in category 2; we updated this based on currently recommended therapies in the UK (Table 1) . Although cefixime has not been recommended for treatment of N. gonorrhoeae since 2011, we retained it in category 1 as it is an ESC.
Descriptive and statistical analyses
Descriptive analyses were used to examine trends in AMR N. gonorrhoeae for 2004-15. Analysis of MDR-NG was restricted to 2011 onwards, to reflect prevalence and risk factors relevant to current treatment guidelines. Modal ceftriaxone and azithromycin MICs were compared between MDR and non-MDR isolates to assess whether there was a drift towards resistance to first-line therapies in MDR-NG among those not yet resistant to these antimicrobials. As resistance to ceftriaxone or azithromycin is included in the definition of MDR-NG, these sub-analyses excluded all isolates which already had decreased susceptibility to ceftriaxone (for comparison of ceftriaxone MICs) or resistance to azithromycin (for comparison of azithromycin MICs). For the risk factor analysis, logistic regression was used to generate ORs initially adjusted for year, age (as a quadratic term, to account for the non-linear relationship) and gender/sexual orientation (groupings: MSM, heterosexual men, all women). Associations with the following variables were examined: ethnicity, residential neighbourhood-level index of multiple deprivation (IMD), number of recent sexual partners (past 3 months), recent sex abroad (past 3 months), previous gonorrhoea infection, symptomatic infection, clinician-coded site of infection, concurrent STIs and HIV status. Multivariable logistic regression analyses were used to determine independent associations, using a forwards model-building approach, with variables retained in the final model based on a P value of 0.10. Exploratory analysis showed evidence of within-clinic (but not within-patient) clustering of MDR-NG, i.e. there was greater similarity in MDR-NG between isolates collected within the same clinic than at different 
.64 mg/L GRASP standard breakpoints. 13 Decreased susceptibility, rather than 'resistance', is used in GRASP for ESCs as treatment failures have been observed across a range of MIC values in some patients but not others.
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clinics. To avoid this resulting in underestimated standard errors, clustering was accounted for in the risk factor analysis using generalized estimating equations under the assumption of an exchangeable correlation matrix. 29 
Results
Sample characteristics
Between 2004 and 2015, 16 242 isolates from 15 781 patients underwent susceptibility testing, with 47.4% of isolates from MSM, 28.2% from heterosexual men and 20.6% from women (Table S1 , available as Supplementary data at JAC Online).
Patterns of antimicrobial resistance in GRASP 2004-15
Resistance to azithromycin was generally low until 2012 (,5%), then increased to 9.8% in 2015 ( Figure 1 ). Decreased susceptibility to ceftriaxone was rare (0.1%), whereas levels of decreased susceptibility to cefixime increased rapidly between 2008 and 2010 (from 3% to 17%), then decreased to 1.1% in 2015 ( Figure 1 ). Resistance to penicillin and ciprofloxacin was widespread (.10%) throughout the study period.
Between 2004 and 2015, the proportion of N. gonorrhoeae isolates fully susceptible to all classes of antimicrobials fell from 80% to 46%, with the proportion resistant to multiple (two or more) classes increasing from 7.3% to 17.5% (Figure 2 ). Resistance to three classes increased between 2008 and 2010 then declined, mirroring trends in cefixime resistance (Figures 1 and 2) . A small number of isolates were resistant to all four classes tested (n " 49; 0.3% overall).
Despite high levels of susceptibility to prevailing first-line therapies immediately following revisions to treatment guidelines in 2005 (from ciprofloxacin to cefixime) 30 and 2011 (from cefixime to ceftriaxone and azithromycin dual therapy), 11 
Prevalence and profile of MDR-NG
Between 2011 and 2015, 3.5% (n " 266) of isolates were MDR-NG, with small increases in prevalence between 2011 and 2013 (from 3.7% to 4.5%) followed by a subsequent decrease to 2.2% in 2015 (v 2 test P " 0.004). The profile of resistance to category 1 antimicrobials among MDR-NG isolates changed over time: 100% were resistant to cefixime in 2011, reducing to 36.9% in 2015, with increases in the proportion resistant to azithromycin over this time frame from 4.2% to 84.3% (P , 0.01) (Figure 4 ). All MDR-NG isolates were resistant to both ciprofloxacin and penicillin, but not spectinomycin, in category 2. Over time, the proportion of MDR-NG resistant to four antimicrobials (cefixime, azithromycin, penicillin and ciprofloxacin) increased from 4.2% in 2011 to 21.1% in 2015. One isolate had resistance/decreased susceptibility to five antimicrobials: ceftriaxone (MIC 0.125 mg/L), cefixime (MIC 0.25 mg/L), azithromycin (MIC 1.0 mg/L), ciprofloxacin (MIC 16 mg/L) and penicillin (MIC 1 mg/L).
In a sub-analysis excluding all isolates with resistance to azithromycin, the MICs of azithromycin for MDR isolates were elevated (modal MIC 0.5 mg/L) compared with those for non-MDR isolates (modal MIC 0.125 mg/L) (Figure 5a ). Similarly, after excluding isolates with decreased susceptibility to ceftriaxone, modal ceftriaxone MICs for MDR isolates were higher (0.03 mg/L) than those for non-MDR isolates (0.002 mg/L) (Figure 5b ). The 
Risk factors for MDR-NG
MDR-NG was more common among heterosexual men than MSM or women (4.6% versus 3.3% and 2.5%, respectively); these differences remained significant after adjustment for other factors ( 
Discussion
Our data demonstrate increases in antimicrobial resistance of N. gonorrhoeae over the past decade in England and Wales, with the proportion of N. gonorrhoeae isolates fully susceptible to all classes of antimicrobials falling from 80% in 2004 to 46% in 2015 and the proportion resistant to two or more classes increasing from 7.3% to 17.5% over this period. Despite high levels of susceptibility to recommended treatments immediately following changes to treatment guidelines in 2005 and 2011, the proportion fully susceptible to these decreased in a matter of years. In 2011-15, 3.5% of isolates were classed as MDR-NG, meaning they were resistant to either azithromycin or an ESC, as well as to penicillin and ciprofloxacin. In 2011, MDR-NG isolates were predominantly resistant to cefixime; however, by 2015 the majority were resistant to azithromycin, with around one in five resistant to both. We also found evidence of drift towards azithromycin resistance among MDR-NG isolates that were not resistant to azithromycin and similar drift towards ceftriaxone resistance. The fact that these elevated ceftriaxone MICs in the MDR isolates were observed in 2014-15 as well as 2011-13 suggests this finding is unlikely to be solely due to the cefixime-resistant ST1407 strains that also have elevated ceftriaxone MICs and were prevalent during 2011-13. 25 Although the risk factor analysis found MDR-NG was more common among isolates from some groups, including heterosexual men and older patients, absolute Clifton et al. differences in prevalence were small, providing little basis for targeted treatment strategies. These findings highlight the importance of continued surveillance and prevention efforts, given the severely limited treatment options available to those with MDR-NG.
Advantages of using the GRASP surveillance data include the large sample size, the ability to look at trends over time and the ability to combine MIC data with demographic, clinical and behavioural information.
GRASP is reasonably representative of gonorrhoea cases across England, although MSM are somewhat over-represented. 31 It is likely that risk characteristics of MSM and heterosexual sexual networks differ, but small numbers of MDR-NG prohibited stratification of risk factor analysis by gender/sexual orientation. Another limitation is the potential for missing data to bias results of the risk factor analysis; for example, completion of behavioural data varied by clinic resulting in more missing data for MSM. Azithromycin MIC data from 2013-14 were adjusted to account for poor organism growth using DST media which underestimated MICs. This adjustment enabled comparisons of antimicrobial resistance over time, but is a crude correction and some misclassification is likely.
In line with low levels of resistance to ceftriaxone generally, 13 few MDR-NG cases had decreased susceptibility to ceftriaxone.
However, MICs of ceftriaxone have been drifting towards resistance in recent years, 15 leaving no room for complacency about the longterm effectiveness of current dual therapy. Our analysis found that the ceftriaxone MICs for MDR-NG isolates were higher than for non-MDR isolates, after excluding those with decreased susceptibility to ceftriaxone, demonstrating how easily MDR-NG with resistance to ceftriaxone could emerge and lead to infections that would be difficult to treat. Although all isolates were susceptible to spectinomycin, this is not considered a viable first-line treatment as resistance has historically developed rapidly when it has been used, it is not effective in treating pharyngeal gonorrhoea and it is currently unavailable in many countries. 5 It should be borne in mind that 96.5% of isolates were not MDR, which is promising in light of efforts to develop point-of-care antimicrobial resistance testing to guide treatment choices. 32 If successful, such tests could identify infections for which previously used therapies would be effective, reducing ceftriaxone use and the selection pressure for resistance.
Despite commentaries on the emerging threat of MDR-NG, 5, 6, 33 the international literature on prevalence and risk factors is scant, perhaps due to lack of consensus on an MDR definition, preventing comparison of prevalence and risk factors. 22, 23, 26 In general, the risk factors for MDR-NG identified here are consistent with those MDR Neisseria gonorrhoeae in England and Wales JAC associated with resistance to some individual antimicrobials in previous studies, including being a heterosexual man (ciprofloxacin, azithromycin, cefixime), 34 the inverse relationships with black Caribbean ethnicity (ciprofloxacin, cefixime), 20, 21 and concurrent STI infection (ciprofloxacin, cefixime). 20, 21 However, previous analyses of GRASP data have found a positive association between HIV and N. gonorrhoeae that was resistant to cefixime, ciprofloxacin or penicillin, 20, 21 in contrast with the inverse relationship with MDR-NG found here. Continued monitoring of the epidemiology of MDR-NG alongside resistance to individual antibiotics is therefore needed.
These data emphasize the loss of susceptibility of N. gonorrhoeae to sequential antimicrobial classes used for treatment and provide the first prevalence estimates of MDR-NG in England and Wales. Although prevalence of MDR-NG was relatively low, many of these isolates were resistant to azithromycin and had ceftriaxone MICs that were higher than those for non-MDR isolates. In the context of limited new treatment options, the emergence of ceftriaxone resistance in MDR-NG could herald the prospect of untreatable N. gonorrhoeae. MDR-NG was generally homogeneously distributed by demographic and behavioural characteristics, with no groups identified as being at especially high risk, highlighting the need for continued culture and susceptibility testing and test of cure among all patients with gonorrhoea. Our findings underline the essential role of timely surveillance to identify and respond to clinically significant changes in AMR N. gonorrhoeae in the coming years. 
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